Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd raised its position in Edwards Lifesciences Co. (NYSE:EW) by 176.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,221 shares of the medical research company’s stock after acquiring an additional 24,398 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Edwards Lifesciences were worth $2,830,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC increased its holdings in Edwards Lifesciences by 10,990.6% in the third quarter. International Assets Investment Management LLC now owns 163,919 shares of the medical research company’s stock valued at $10,817,000 after buying an additional 162,441 shares in the last quarter. Forsta AP Fonden boosted its stake in shares of Edwards Lifesciences by 12.0% during the 3rd quarter. Forsta AP Fonden now owns 134,000 shares of the medical research company’s stock worth $8,843,000 after acquiring an additional 14,400 shares in the last quarter. Smithbridge Asset Management Inc. DE grew its holdings in shares of Edwards Lifesciences by 20.2% in the 3rd quarter. Smithbridge Asset Management Inc. DE now owns 13,086 shares of the medical research company’s stock worth $864,000 after acquiring an additional 2,202 shares during the period. Forbes J M & Co. LLP increased its stake in Edwards Lifesciences by 6.1% in the 3rd quarter. Forbes J M & Co. LLP now owns 5,610 shares of the medical research company’s stock valued at $370,000 after purchasing an additional 325 shares in the last quarter. Finally, abrdn plc raised its holdings in Edwards Lifesciences by 1.7% during the third quarter. abrdn plc now owns 1,311,844 shares of the medical research company’s stock worth $85,847,000 after purchasing an additional 22,271 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Citigroup raised their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Truist Financial reaffirmed a “hold” rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Finally, Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Down 0.8 %

Shares of EW opened at $72.72 on Tuesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock’s 50-day moving average is $72.83 and its two-hundred day moving average is $70.13. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market cap of $42.89 billion, a PE ratio of 10.43, a P/E/G ratio of 4.82 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.